Skip to main content
SpringerLink
Log in

Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy

  • Original article
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

Introduction

Polytherapy is often required to treat the comorbidity of hypertension and hyperlipidemia. Fixed-dose co-formulation, rather than free combinations, simplifies medication taking and also improves adherence to medication, which is the key for a successful management of these conditions.

Aim

To determine the number of patients potentially eligible for treatment with triple fixed-dose atorvastatin/perindopril/amlodipine (CTAPA), and to estimate if an unmet medical need exists among CTAPA free combination treated patients.

Methods

This observational retrospective study was based on administrative databases of 3 Italian Local Health Units. The cohort comprised adult patients with at least one prescription of amlodipine and perindopril (either as free combination or co-formulated) and atorvastatin during 2014. Follow-up period started on the date of prescription of the 3 molecules (index date) and lasted 1 year. Adherence to CTAPA was analyzed during follow-up, by using the proportion of days covered (PDC).

Results

2292 patients (9.1 per 10,000 beneficiaries) had a prescription for CTAPA as free combination. Only 1249 (54.5%) were adherent to the therapy (PDC ≥ 80%); among them, a small percentage required dosage modification. The number of patients with CTAPA increased during the study period. Discontinuation of drugs prescribed the year before interested 582 patients in 2014, and 522 in 2015. Considering the Italian national population (n = 60,782,668), it was estimated that 69,542 hypertensive patients could be eligible for fixed-dose CTAPA during 2014.

Conclusions

Real-world analysis among patients with free combination therapy can be applied to estimate the eligible population for fixed combination, and to evaluate the appropriateness of their prescriptions. Moreover, fixed-dose CTAPA could effectively improve adherence, which was calculated to be low in the free combination cohort.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. World Health Organization. Cardiovascular diseases (CVDs). [Internet]. http://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed 1 May 2019.

  2. Erhardt L, Moller R, Puig JG. Comprehensive cardiovascular risk management–what does it mean in practice? Vasc Health Risk Manag. 2007;3(5):587–603.

    PubMed  PubMed Central  Google Scholar 

  3. Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin Gemini Study). J Clin Hypertens. 2005;7(5):264–73.

    Article  CAS  Google Scholar 

  4. Dézsi CA. Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: a subgroup analysis from the PAPA-CAD study. J Int Med Res. 2018;46(5):1902–9.

    Article  Google Scholar 

  5. Borghi C. Interactions between hypercholesterolemia and hypertension: implications for therapy. Curr Opin Nephrol Hypertens. 2002;11(5):489–96.

    Article  Google Scholar 

  6. Bertrand ME, Vlachopoulos C, Mourad J-J. Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipine. Am J Cardiovasc Drugs. 2016;16(4):241–53.

    Article  CAS  Google Scholar 

  7. Watson S, Gupta A, Poulter N. Prevention of coronary and stroke events with perindopril, amlodipine and atorvastatin in combination: sub-group analysis of the anglo-scandinavian cardiac outcomes trial (ASCOT). J Hypertens [Internet]. 2014;32(e-Supplement 1). http://file:///C:/Users/AnnaGirardi/Downloads/odborna%20publikacia_Post%20hoc%20ASCOT_LLA.pdf .

  8. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14.

    Article  Google Scholar 

  9. Katsiki N, Athyros VG, Karagiannis A. Single-pill combinations: a therapeutic option or necessity for vascular risk treatment? J Drug Assess. 2013;2(1):67–71.

    Article  Google Scholar 

  10. Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific Region. Circulation. 2005;112(22):3384–90.

    Article  Google Scholar 

  11. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.

    Article  Google Scholar 

  12. Agenzia Italiana del Farmaco (AIFA). Guideline for the classification and conduction of the observational studies on medicines. [Internet]. 2010. https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/CIRCULARS/Circular%2031st%20May%202010.pdf.

  13. http://demo.istat.it/pop2014/index.html. Accessed 1 May 2019.

  14. Crim MT, Yoon SSS, Ortiz E, Wall HK, Schober S, Gillespie C, et al. National surveillance definitions for hypertension prevalence and control among adults. Circ Cardiovasc Qual Outcomes. 2012;5(3):343–51.

    Article  Google Scholar 

  15. Volpe M, Tocci G, Trimarco B, Rosei EA, Borghi C, Ambrosioni E, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens. 2007;25(7):1491–8.

    Article  CAS  Google Scholar 

  16. Tocci G, Nati G, Cricelli C, Parretti D, Lapi F, Ferrucci A, Borghi C, Volpe M. Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. J Hum Hypertens. 2017;31(4):258–62.

    Article  CAS  Google Scholar 

  17. Degli Esposti L, Perrone V, Veronesi C, Gambera M, Nati G, Perone F, et al. Modifications in drug adherence after switch to fixed-dose combination of perindopril/amlodipine in clinical practice. Results of a large-scale Italian experience. The amlodipine–perindopril in real settings (AMPERES) study. Curr Med Res Opin. 2018;22:1–7.

    Google Scholar 

  18. Selak V, Webster R. Polypills for the secondary prevention of cardiovascular disease: effective in improving adherence but are they safe? Ther Adv Drug Saf. 2018;9(2):157–62.

    Article  Google Scholar 

  19. Volpe M, Battistoni A, Gallo G, Rubattu S, Tocci G, Writing Committee; Scientific Societies. Executive summary of the 2018 joint consensus document on cardiovascular disease prevention in Italy. High Blood Press Cardiovasc Prev. 2018;25(3):327–41.

    Article  Google Scholar 

  20. Volpe M, Tocci G, de la Sierra A, Kreutz R, Laurent S, Manolis AJ, Tsioufis K. Personalised single-pill combination therapy in hypertensive patients: an update of a practical treatment platform. High Blood Press Cardiovasc Prev. 2017;24(4):463–72.

    Article  CAS  Google Scholar 

  21. Wang Y, Kuang ZM, Feng SJ, Jiang L, Chen QX, Ji XY, Cheng WL, Hu HJ. Combined antihypertensive and statin therapy for the prevention of cardiovascular events in patients with hypertension without complications: protocol for a systematic review and meta-analysis. BMJ Open. 2018;8(5):e019719.

    Article  Google Scholar 

  22. Tocci G, Presta V, Citoni B, et al. Favorable impact of statin use on diastolic blood pressure levels: analysis of a large database of 24-hour ambulatory blood pressure monitoring. J Hypertens. 2017;35:2086–94.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Health Economics and Outcomes Research, Clicon S.r.l., Via Salara, 36, 48121, Ravenna, Italy

    Valentina Perrone, Chiara Veronesi & Luca Degli Esposti

  2. Local Pharmaceutical Service, Bergamo Local Health Authority, Bergamo, Italy

    Marco Gambera

  3. Italian Society of General Practice, Roma, Italy

    Giulio Nati

  4. Local Health Unit, Caserta, Italy

    Francesco Perone

  5. General Practitioner of Agenzia di Tutela e Salute della provincia di Bergamo, Bergamo, Italy

    Paola Fausta Tagliabue

  6. Division of Cardiology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant’Andrea Hospital, Rome, Italy

    Massimo Volpe

  7. IRCCS Neuromed, Pozzilli, Italy

    Massimo Volpe

Authors
  1. Valentina Perrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiara Veronesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Gambera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giulio Nati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesco Perone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paola Fausta Tagliabue
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luca Degli Esposti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Massimo Volpe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valentina Perrone.

Ethics declarations

Conflict of interest

Manuscript development was supported by unconditional funding from Servier. MV received honoraria for speaking bureau or scientific consulting Servier.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Perrone, V., Veronesi, C., Gambera, M. et al. Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy. High Blood Press Cardiovasc Prev 26, 399–404 (2019). https://doi.org/10.1007/s40292-019-00336-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40292-019-00336-2

Keywords

Search

Navigation